FAQ on Quantum BioPharma Ltd.'s Corporate Update and Strategic Initiatives
Summary
What is Quantum BioPharma Ltd. focused on?
Quantum BioPharma Ltd. is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in various stages of development.
What recent corporate updates has Quantum BioPharma announced?
The company announced the grant of 60,000 restricted share units under its equity incentive plan and the settlement of outstanding debt owed to arm’s length parties by issuing Class B Shares at a deemed price of US$6.75.
What is Lucid-MS?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is UNBUZZD(TM) and how is Quantum BioPharma involved?
UNBUZZD(TM) is a product invented by Quantum BioPharma, which has spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains a 25.71% ownership in Celly Nutrition and receives royalty payments from sales of UNBUZZD(TM).
How can investors stay updated on Quantum BioPharma Ltd.?
Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.
What does Quantum BioPharma’s agreement with Celly Nutrition entail?
The agreement includes royalty payments of 7% of sales from UNBUZZD(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains rights to develop similar products for pharmaceutical and medical uses.
What is the significance of Quantum BioPharma’s corporate updates?
These updates reflect Quantum BioPharma’s ongoing efforts to strengthen its financial position and continue its research and development in innovative treatments for neurodegenerative and metabolic disorders.
Where can I view the full press release about Quantum BioPharma’s corporate update?
The full press release can be viewed at https://ibn.fm/7WDeK.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119464